Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Presentation TCT 2023

TCT 423: Long-term Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition with Evolocumab and Aortic Stenosis Events – An Analysis from FOURIER and FOURIER-OLE

Presenter: Prakriti Gaba

October 26, 2023

Presentation ESC 2022

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Presenter: Michelle L. O’Donoghue

August 29, 2022

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

Presentation AHA 2017

Insights from the FOURIER Trial

Presenter: Marc P. Bonaca

November 15, 2017

Presentation TCT 2017

FOURIER Trial: Topline Findings and Practice Implications

Presenter: Robert A. Harrington, Evan A. Stein, Wolfgang Koenig

November 01, 2017

Presentation TCT 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

Presentation ACC 2017

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Presenter: Robert Giugliano

March 19, 2017

Advertisement

TCT 423: Long-term Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition with Evolocumab and Aortic Stenosis Events – An Analysis from FOURIER and FOURIER-OLE

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Insights from the FOURIER Trial

FOURIER Trial: Topline Findings and Practice Implications

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content